Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TSN-084 by Tyligand Biotechnology (Shanghai) for Gastric Cancer: Likelihood of Approval
TSN-084 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase I for Gastric Cancer. According to GlobalData,...